Last reviewed · How we verify

NCT07254988

Gut Peptides and Bone Remodeling in Children With Neuromuscular Disorders

Terminated NA Last updated 16 April 2026
What this trial tests

NA trial testing Meal test in Spinal Muscular Atrophy (SMA) in 3 participants. Terminated before completion.

Timeline
24 March 2023
Primary endpoint
1 December 2025
1 December 2025

Quick facts

Lead sponsorUniversity of Copenhagen
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingsingle
Primary purposebasic science
Enrollment3
Start date24 March 2023
Primary completion1 December 2025
Estimated completion1 December 2025
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

University of Copenhagen

Who can join

Adults 10 to 17, any sex, with Spinal Muscular Atrophy (SMA) or Cerebral Palsy (CP). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Both GIP and GLP-2 reduce bone resorption (measured as CTX) in healthy adult individuals. In this study, we will investigate whether GIP and GLP-2 reduce CTX in children with spinal muscular atrophy, duchenne muscular dystrophy, or cerebral palsy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Meal test

Trials testing the same drug.

Other recruiting trials for Spinal Muscular Atrophy (SMA)

Currently open trials in the same condition.

Other University of Copenhagen trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07254988.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing